Journal article
Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis
Abstract
The RisedronatE and ALendronate (REAL) study provided a unique opportunity to conduct cost-effectiveness analyses based on effectiveness data from real-world clinical practice. Using a published osteoporosis model, the researchers found risedronate to be cost-effective compared to generic or brand alendronate for the treatment of Canadian postmenopausal osteoporosis in patients aged 65 years or older.IntroductionThe REAL study provides robust …
Authors
Grima DT; Papaioannou A; Thompson MF; Pasquale MK; Adachi JD
Journal
Osteoporosis International, Vol. 19, No. 5, pp. 687–697
Publisher
Springer Nature
Publication Date
May 2008
DOI
10.1007/s00198-007-0504-z
ISSN
0937-941X